Cardiovascular Systems Stock

Cardiovascular Systems EBIT

Delisted

The EBIT of Cardiovascular Systems (CSII) as of Aug 26, 2026 is -35.81 M USD. In the previous year, EBIT was -11.93 M USD — a change of 200.06% (lower).

EBIT

-35.81 MUSD

YoY

200.06%

Last updated:

In 2026, Cardiovascular Systems's EBIT was -35.81 M USD, a 200.06% increase from the -11.93 M USD EBIT recorded in the previous year.

The Cardiovascular Systems EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2020
-26.77 M USD
Jan 1, 2021
-11.93 M USD
Jan 1, 2022
-35.81 M USD
Jan 1, 2023 (e)
-27.91 M USD
Jan 1, 2024 (e)
-20.48 M USD
Jan 1, 2025 (e)
-12.21 M USD
Jan 1, 2026 (e)
-17.92 M USD
Jan 1, 2027 (e)
-22.38 M USD
The Cardiovascular Systems EBIT history
YEAREBITYoY
est-22.38 MUSD+24.84%
est-17.92 MUSD+46.77%
est-12.21 MUSD-40.36%
est-20.48 MUSD-26.64%
est-27.91 MUSD-22.04%
-35.81 MUSD+200.06%
-11.93 MUSD-55.43%
-26.77 MUSD+3,145.09%
-825,000.00USD-123.17%
3.56 MUSD-324.10%
-1.59 MUSD-97.16%
-56.02 MUSD+71.66%
-32.64 MUSD-2.54%
-33.49 MUSD+49.38%
-22.42 MUSD+54.98%
-14.47 MUSD+64.22%
-8.81 MUSD-61.53%
-22.90 MUSD-33.11%
-34.23 MUSD-1,629.62%
2.24 MUSD-106.49%
-34.49 MUSD+1.25%
-34.07 MUSD+84.73%
-18.44 MUSD-2,640.22%
726,000.00USD-119.15%
-3.79 MUSD
Access this data via the Eulerpool API

Cardiovascular Systems Revenue

Cardiovascular Systems Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
236.55 M USD
-26.77 M USD
-27.24 M USD
Jan 1, 2021
258.97 M USD
-11.93 M USD
-13.42 M USD
Jan 1, 2022
236.22 M USD
-35.81 M USD
-36.93 M USD
Jan 1, 2023 (e)
255.57 M USD
-27.91 M USD
-26.28 M USD
Jan 1, 2024 (e)
279.77 M USD
-20.48 M USD
-18.44 M USD
Jan 1, 2025 (e)
327.47 M USD
-12.21 M USD
-11.60 M USD
Jan 1, 2026 (e)
342.89 M USD
-17.92 M USD
-19.12 M USD
Jan 1, 2027 (e)
349.93 M USD
-22.38 M USD
-23.68 M USD

Cardiovascular Systems Margins

Cardiovascular Systems stock margins

The Cardiovascular Systems margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cardiovascular Systems. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cardiovascular Systems.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
79.39 %
-11.32 %
-11.51 %
Jan 1, 2021
76.39 %
-4.61 %
-5.18 %
Jan 1, 2022
73.14 %
-15.16 %
-15.63 %
Jan 1, 2023 (e)
73.14 %
-10.92 %
-10.28 %
Jan 1, 2024 (e)
73.14 %
-7.32 %
-6.59 %
Jan 1, 2025 (e)
73.14 %
-3.73 %
-3.54 %
Jan 1, 2026 (e)
73.14 %
-5.23 %
-5.58 %
Jan 1, 2027 (e)
73.14 %
-6.39 %
-6.77 %

Cardiovascular Systems Stock analysis

What does Cardiovascular Systems do? Cardiovascular Systems Inc. (CSI) is a US medical technology company founded in 1989. The company is headquartered in St. Paul, Minnesota and employs approximately 1,000 employees worldwide. CSI develops, manufactures, and distributes innovative devices for the treatment of vascular diseases. The business model of CSI is based on the development and marketing of medical devices for minimally invasive treatment of vascular diseases. The company generates a significant portion of its revenues through the sale of its products to hospitals and specialized healthcare facilities. Additionally, CSI also offers training and educational programs for doctors and medical personnel to optimize the use of their devices. CSI operates in two main segments: peripheral arterial disease (PAD) and coronary heart disease (CHD). The PAD segment includes devices for the treatment of vascular diseases outside of the heart, such as peripheral arterial occlusive disease (PAOD). This includes the Diamondback-360® catheter and the Stealth 360® catheter, both used for plaque ablation in the arteries. The CHD segment focuses on the treatment of heart diseases such as coronary artery disease (CAD). This includes the Orbital Atherectomy System (OAS), a device that can reduce the use of stents in patients with more severe coronary artery narrowings. CSI's core product is the Diamondback-360® catheter, which was approved by the US Food and Drug Administration (FDA) in 2013. This device consists of a rotating catheter inserted into the artery to remove plaque causing vessel narrowing. The Diamondback-360 catheter is used for the treatment of PAD and has the potential to significantly improve patients' quality of life. Another important product from CSI is the Orbital Atherectomy System (OAS), used for the treatment of CAD. The OAS system is a rotating catheter that can remove plaque in the coronary arteries to improve blood flow. The use of OAS can potentially avoid costly and invasive procedures such as coronary angiography or bypass. In summary, Cardiovascular Systems Inc. is a leading company in the development and production of innovative devices for minimally invasive treatment of vascular diseases. The company specializes in two main segments, peripheral arterial disease and coronary heart disease. With products like the Diamondback-360 catheter and the Orbital Atherectomy System, CSI has established itself as a reliable provider of high-quality medical devices. Through training and educational programs, CSI also contributes to improving medical care and the development of treatment methods. Cardiovascular Systems is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Cardiovascular Systems's EBIT

Cardiovascular Systems's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Cardiovascular Systems's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Cardiovascular Systems's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Cardiovascular Systems’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Cardiovascular Systems stock

EBIT of Cardiovascular Systems is -35.81 M USD in 2026.

EBIT of Cardiovascular Systems changed from -11.93 M USD to -35.81 M USD, representing a 200.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Cardiovascular Systems since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Cardiovascular Systems historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Cardiovascular Systems

All Key Metrics — Cardiovascular Systems